On February 10, 2020 Diverse Biotech, Inc. www.diversebiotech.com has reported it has been selected to present at the upcoming BIO CEO & Investor Conference in New York on February 11th. View Source (Press release, Diverse Biotech, FEB 10, 2020, View Source [SID1234554119])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, Diverse Biotech has announced that a paper regarding cannabinoid-related gene expression was accepted by the Journal of Applied Cell Biology. The paper should be published in the next 3-4 weeks.

"We are truly excited to continue to discuss our ground-breaking technology. In addition, the gene expression paper is tremendous because it highlights that a variety of cell lines including glioblastoma, pancreatic cancer, melanoma, actinic keratosis, squamous cell carcinoma, and normal skin – all express genes that suggest they will be responsive to exogenous cannabinoid treatment," said Stella Vnook, Diverse Biotech’s Chief Executive Officer.